We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Discovery of key mechanism may fight lenalidomide resistance in a number of myeloma
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Discovery of key mechanism may fight lenalidomide resistance in a number of myeloma
Discovery of key mechanism may fight lenalidomide resistance in a number of myeloma
Health

Discovery of key mechanism may fight lenalidomide resistance in a number of myeloma

Last updated: April 10, 2025 1:39 pm
Editorial Board Published April 10, 2025
Share
SHARE

Proposed mannequin of mechanism underlying the function of ADAR1 in regulating resistance to IMiDs in MM. Credit score: Blood (2024). DOI: 10.1182/blood.2024024429

A brand new examine performed by researchers from the Most cancers Science Institute of Singapore (CSI Singapore) on the Nationwide College of Singapore has uncovered a key mechanism behind lenalidomide resistance in a number of myeloma (MM), providing new insights into potential methods for enhancing remedy outcomes and overcoming drug resistance.

The staff, led by Dr. Teoh Phaik Ju and Dr. Koh Mun Yee, along with Professor Chng Wee Joo and Affiliate Professor Polly Chen, recognized a gene known as ADAR1, which encodes an RNA-editing enzyme as a key think about suppressing the immune response triggered by lenalidomide—an immune-stimulating drug, important to killing MM cells. The findings have been revealed within the journal Blood on 13 March 2025.

ADAR1’s function in lenalidomide resistance in MM

MM is a sort of most cancers that impacts plasma cells within the bone marrow. Whereas standard-of-care therapies like lenalidomide, an immunomodulatory drug (IMiD), have improved survival charges for a lot of MM sufferers, a big quantity nonetheless expertise relapse as a result of growth of drug resistance.

Lenalidomide works by binding to a protein known as cereblon (CRBN), which breaks down a number of proteins which can be important for MM cell survival and progress. Nevertheless, many sufferers finally cease responding to the drug, resulting in illness relapse.

Whereas 20% to 30% of the resistance circumstances have been linked to defects in CRBN and its related elements, the underlying mechanisms in most resistance circumstances have remained poorly understood. This examine experiences new findings demonstrating that ADAR1 abnormalities result in a suppressed immune system in IMiD-resistant MM circumstances.

Overcoming drug resistance

ADAR1 inhibits lenalidomide’s exercise by modifying double-stranded RNA (dsRNA), thus hindering the immune response and lowering the effectiveness of the drug in combating MM progress and proliferation. The researchers found that by lowering the degrees of ADAR1 and growing dsRNA accumulation in MM cells, they may enhance the sensitivity of the cells to lenalidomide. This might, in flip, result in the activation of the immune responses and kill the MM cells.

The invention provides a brand new layer to the understanding of how MM sufferers could turn into immune to IMiD, highlighting the function of dsRNA pathways past the beforehand understood CRBN pathway.

The findings additionally counsel that focusing on ADAR1 and the dsRNA pathway may provide promising methods to beat resistance to lenalidomide in MM. As medical trials proceed to discover the potential of recent IMiD analogs, akin to CRBN-E3 ligase modulators (CELMoDs) and different medication with comparable pharmacological profile, combining these therapies with ADAR1 inhibitors could present a simpler strategy to sort out drug resistance and enhance affected person outcomes.

With ADAR1 inhibitors at the moment in preclinical growth, this technique holds nice promise for advancing remedy choices for MM. As well as, the analysis staff plans to additional examine ADAR1’s function in different splicing, a post-transcriptional gene regulatory mechanism, in MM, which may uncover much more alternatives for therapies.

Extra data:
Mun Yee Koh et al, The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in a number of myeloma, Blood (2024). DOI: 10.1182/blood.2024024429

Journal data:
Blood

Supplied by
Nationwide College of Singapore

Quotation:
Discovery of key mechanism may fight lenalidomide resistance in a number of myeloma (2025, April 10)
retrieved 10 April 2025
from https://medicalxpress.com/information/2025-04-discovery-key-mechanism-combat-lenalidomide.html

This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.

You Might Also Like

Stopping heat-related sickness in kids as temperatures rise

AI-powered digital staining of biopsies for transplant diagnostics

New examine maps 4 key pathways to Alzheimer’s illness

A mathematical perspective presents perception into the placenta’s position and functioning

‘Chaotic and deeply horrifying’: As soon as a world gold commonplace, US authorities well being steering is falling aside

TAGGED:combatdiscoverykeylenalidomidemechanismmultiplemyelomaresistance
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Hong Kong Elections: How ‘Patriots Only’ Bolsters Beijing’s Grip
World

Hong Kong Elections: How ‘Patriots Only’ Bolsters Beijing’s Grip

Editorial Board December 20, 2021
Alex Jones Reaches Out to Justice Dept. About Jan. 6 Interview
Yr in assessment: Influential individuals who died in 2024
Shedeur Sanders plummets in NFL Draft as Giants land Toledo DT Darius Alexander
Save Earth Mission’s Asset, Yes Coin, Creates History by Developing World’s Most Rewarding Ecosystem

You Might Also Like

How physique mass index impacts breast most cancers threat in postmenopausal ladies with and with out heart problems
Health

How physique mass index impacts breast most cancers threat in postmenopausal ladies with and with out heart problems

July 7, 2025
Tracing dormant most cancers cells: Chemotherapy spurs awakening, however senolytic medicine might forestall relapse
Health

Tracing dormant most cancers cells: Chemotherapy spurs awakening, however senolytic medicine might forestall relapse

July 7, 2025
Cerebral cortex synapses transmit indicators extra reliably than these in rear mind areas
Health

Cerebral cortex synapses transmit indicators extra reliably than these in rear mind areas

July 7, 2025
Lacking useful micro organism in toddler guts linked to rising bronchial asthma and allergy instances
Health

Lacking useful micro organism in toddler guts linked to rising bronchial asthma and allergy instances

July 7, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?